Skip to main content

Advertisement

SpringerLink
Log in

Evidence basis for treatment of spasticity

  • Invited Commentary
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Young RR: Spasticity: a review. Neurology 1994, 44 (suppl 9):12S-20S.

    Google Scholar 

  2. Shakespeare DT, Boggild M, Young C: Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2001, 1:1–26.

    Google Scholar 

  3. Matthews B: Treatment of symptoms. In McAlpine’s Multiple Sclerosis, edn 3. Edited by Compton A, Ebers G, Lassman H, et al. London: Churchill Livingstone; 1998:449–455.

    Google Scholar 

  4. Feldman RG, Kelly Hayes M, Conomoy JP: Baclofen for spasticity in multiple sclerosis: double blind crossover and three year study. Neurology 1978, 28:1094–1098.

    PubMed  CAS  Google Scholar 

  5. Basmajian J, Yucel V: Effects of GABA-derivative (BA-34647) on spasticity. Am J Phys Med 1974, 53:223–228.

    PubMed  CAS  Google Scholar 

  6. Sawa GM, Paty DW: The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979, 6:351–354.

    PubMed  CAS  Google Scholar 

  7. Sachais B, Logue J, Carey M: Baclofen, a new antispastic drug. Arch Neurol 1977, 34:422–428.

    PubMed  CAS  Google Scholar 

  8. Brar S, Smith MB, Nelso LM, et al.: Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991, 72:186–189.

    PubMed  CAS  Google Scholar 

  9. Lapierre Y, Elie R, Tetrault LP: The anti-spasticity effect of Ba 3467. A GABA derivative. Curr Ther Res 1974, 16:1059–1068.

    PubMed  CAS  Google Scholar 

  10. United Kingdom Tizanidine Trial Group: A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. The United Kingdon Tizanidine Trial Group. Neurology 1994, 44(suppl 9):S70-S78.

    Google Scholar 

  11. Smith C, Birnbaum G, Carter JL, et al.: Tizanidine treatment of spasticity caused by multiple sclerosis: results of a doubleblind, placebo-controlled trial. Neurology 1994, 44(suppl 9):S34-S42.

    PubMed  CAS  Google Scholar 

  12. Smolenski C, Muff S, Smolneski-Kauatz S: A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103–282) and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981, 7:374–383.

    PubMed  CAS  Google Scholar 

  13. Stien R, Nordal HJ, Oftedal SI, Slettebo M: The treatment of spasticity in multiple sclerosis: a double-blind trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987, 75:190–194.

    PubMed  CAS  Google Scholar 

  14. Pelkofer M, Paulig M: Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam, and tizanidine in spastic movement disorders of the lower extremities. Med Klinik 1989, 84:5–8.

    Google Scholar 

  15. Bass B, Weinshenker B, Rice GP, et al.: Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988, 15:15–19.

    PubMed  CAS  Google Scholar 

  16. Mueller ME, Gruenthal M, Olson WL, Olson WH Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997, 78:521–524.

    Article  PubMed  CAS  Google Scholar 

  17. Gelenberg A, Poskanzer DC: The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973, 23:1313–1315.

    PubMed  CAS  Google Scholar 

  18. Luisto M, Moller K, Nuutila A, Palo J: Dantrolene sodium in chronic spasticity of varying etiology. Acta Neruol Scand 1982, 65:355–362.

    CAS  Google Scholar 

  19. Schmidt R, Lee R, Spehlman R: Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976, 39:350–356.

    PubMed  CAS  Google Scholar 

  20. Barnes M: Management of spasticity—pharmacological agents. In Priniciples of Treatment of Multiple Sclerosis. Edited by Hawkins CP, Wolinsky JS. Oxford: Butterworth Heinemann; 2000:184–200.

    Google Scholar 

  21. From A, Heltberg A: A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975, 51:158–166.

    Article  PubMed  CAS  Google Scholar 

  22. Ungerleider JT, Andrysiak T, Fairbanks L, et al.: Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Substance Abuse 1987, 7:39–50.

    CAS  Google Scholar 

  23. Baker D, Pryce G, Croxford JL, et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84–87.

    Article  PubMed  CAS  Google Scholar 

  24. Penn RD, Savoy SM, Corcos D, et al.: Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989, 320:1517–1521.

    Article  PubMed  CAS  Google Scholar 

  25. Penn RD: Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992, 77:236–240.

    PubMed  CAS  Google Scholar 

  26. Ordia JI, Fischer E, Adamski E, Spatz EL: Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996, 85:453–457.

    Google Scholar 

  27. Ochs G, Struppler A, Meyerson BA, et al.: Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 1989, 52:933–939.

    PubMed  CAS  Google Scholar 

  28. van Hilten BJ, van de Beek WJ, Hoff JL, et al.: Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000, 343:625–630.

    Article  PubMed  Google Scholar 

  29. Gerszten PC, Albright AL, Barry MJ: Effect on ambulation of continuous intrathecal baclofen infusion. Pediatric Neurosurg 1997, 27:40–44.

    Article  CAS  Google Scholar 

  30. Becker WJ, Harris CJ, Long ML, et al.: Long term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurosci 1995, 22:208–217.

    CAS  Google Scholar 

  31. Middel B, Kuipers-Pumeijer H, Bouma J, et al.: Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997, 63:204–209.

    Article  PubMed  CAS  Google Scholar 

  32. Gianino JM, York MM, Paice JA, Shott S: Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neuroscience Nursing 1998, 30:47–54.

    CAS  Google Scholar 

  33. Creedon SD, Dijkers MP, Hinderer SR: Intrathecal baclofen for severe spasticity: a meta-analysis. Int J Rehab Health 1997, 3:171–185.

    Google Scholar 

  34. Hatheway CL, Dang C: Immunogenicity of neurotoxins of Clostridium botulinum. In Therapy with Botulinum Toxin. Edited by Janovic J, Hallett M. New York: Marcel Dekker; 1994:93–107.

    Google Scholar 

  35. Snow BJ, Tsui JK, Bhatt MH, et al.: Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990, 28:512–515.

    Article  PubMed  CAS  Google Scholar 

  36. Ward A: Management of spasticity—botulinum toxin. In Principles of Treatments in Multiple Sclerosis. Edited by Hawkins CP, Wolinsky JS. Oxford: Butterworth Heinemann; 2000:201–228.

    Google Scholar 

  37. Brin MF: Spasticity: Etiology, Management, and the Role of Botulinium Toxin Type A. New York: Wiley; 1997.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, 75 Francis Street, 02115, Boston, MA, USA

    David M. Dawson MD

Authors
  1. David M. Dawson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dawson, D.M. Evidence basis for treatment of spasticity. Curr Neurol Neurosci Rep 1, 501–506 (2001). https://doi.org/10.1007/s11910-001-0051-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0051-5

Keywords

Search

Navigation